203 related articles for article (PubMed ID: 16142744)
1. Prevalence of Barrett's esophagus in systemic sclerosis.
Wipff J; Allanore Y; Soussi F; Terris B; Abitbol V; Raymond J; Chaussade S; Kahan A
Arthritis Rheum; 2005 Sep; 52(9):2882-8. PubMed ID: 16142744
[TBL] [Abstract][Full Text] [Related]
2. Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma.
Weston AP; Badr AS; Topalovski M; Cherian R; Dixon A; Hassanein RS
Am J Gastroenterol; 2000 Feb; 95(2):387-94. PubMed ID: 10685740
[TBL] [Abstract][Full Text] [Related]
3. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
[TBL] [Abstract][Full Text] [Related]
4. Esophageal involvement in scleroderma: gastroesophageal reflux, the common problem.
Ntoumazios SK; Voulgari PV; Potsis K; Koutis E; Tsifetaki N; Assimakopoulos DA
Semin Arthritis Rheum; 2006 Dec; 36(3):173-81. PubMed ID: 17045629
[TBL] [Abstract][Full Text] [Related]
5. Low incidence of adenocarcinoma and high-grade intraepithelial neoplasia in patients with Barrett's esophagus: a prospective cohort study.
Martinek J; Benes M; Brandtl P; Hucl T; Vasicek M; Voska L; Lanska V; Nosek V; Spicak J
Endoscopy; 2008 Sep; 40(9):711-6. PubMed ID: 18698534
[TBL] [Abstract][Full Text] [Related]
6. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.
Cooper BT; Chapman W; Neumann CS; Gearty JC
Aliment Pharmacol Ther; 2006 Mar; 23(6):727-33. PubMed ID: 16556174
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Barrett's oesophagus related to systemic sclerosis: a 3-year EULAR Scleroderma Trials and Research prospective follow-up study.
Wipff J; Coriat R; Masciocchi M; Caramaschi P; Derk CT; Hachulla E; Riccieri V; Mouthon L; Krasowska D; Ananyeva LP; Kahan A; Matucci-Cerinic M; Chaussade S; Allanore Y
Rheumatology (Oxford); 2011 Aug; 50(8):1440-4. PubMed ID: 21415021
[TBL] [Abstract][Full Text] [Related]
8. Autofluorescence endoscopy in surveillance of Barrett's esophagus: a multicenter randomized trial on diagnostic efficacy.
Borovicka J; Fischer J; Neuweiler J; Netzer P; Gschossmann J; Ehmann T; Bauerfeind P; Dorta G; Zürcher U; Binek J; Meyenberger C
Endoscopy; 2006 Sep; 38(9):867-72. PubMed ID: 16981102
[TBL] [Abstract][Full Text] [Related]
9. The association between alcohol and reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
Anderson LA; Cantwell MM; Watson RG; Johnston BT; Murphy SJ; Ferguson HR; McGuigan J; Comber H; Reynolds JV; Murray LJ
Gastroenterology; 2009 Mar; 136(3):799-805. PubMed ID: 19162028
[TBL] [Abstract][Full Text] [Related]
10. Esophagitis: incidence and risk of esophageal adenocarcinoma--a population-based cohort study.
Lassen A; Hallas J; de Muckadell OB
Am J Gastroenterol; 2006 Jun; 101(6):1193-9. PubMed ID: 16771936
[TBL] [Abstract][Full Text] [Related]
11. Glycemic index, carbohydrate and fiber intakes and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
Mulholland HG; Cantwell MM; Anderson LA; Johnston BT; Watson RG; Murphy SJ; Ferguson HR; McGuigan J; Reynolds JV; Comber H; Murray LJ
Cancer Causes Control; 2009 Apr; 20(3):279-88. PubMed ID: 18839322
[TBL] [Abstract][Full Text] [Related]
12. Gastroesophageal reflux and related pathology in adults who were born with esophageal atresia: a long-term follow-up study.
Taylor AC; Breen KJ; Auldist A; Catto-Smith A; Clarnette T; Crameri J; Taylor R; Nagarajah S; Brady J; Stokes K
Clin Gastroenterol Hepatol; 2007 Jun; 5(6):702-6. PubMed ID: 17544997
[TBL] [Abstract][Full Text] [Related]
13. Barrett's esophagus at a tertiary care center: association of age on incidence and prevalence of dysplasia and adenocarcinoma.
Guardino JM; Khandwala F; Lopez R; Wachsberger DM; Richter JE; Falk GW
Am J Gastroenterol; 2006 Oct; 101(10):2187-93. PubMed ID: 17032182
[TBL] [Abstract][Full Text] [Related]
14. Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia.
Anandasabapathy S; Jhamb J; Davila M; Wei C; Morris J; Bresalier R
Cancer; 2007 Feb; 109(4):668-74. PubMed ID: 17211862
[TBL] [Abstract][Full Text] [Related]
15. Barrett's metaplasia and adenocarcinoma of the esophagus in scleroderma.
Katzka DA; Reynolds JC; Saul SH; Plotkin A; Lang CA; Ouyang A; Jimenez S; Cohen S
Am J Med; 1987 Jan; 82(1):46-52. PubMed ID: 3799692
[TBL] [Abstract][Full Text] [Related]
16. Barrett's esophagus: a retrospective analysis of 13 years surveillance.
Switzer-Taylor V; Schlup M; Lübcke R; Livingstone V; Schultz M
J Gastroenterol Hepatol; 2008 Sep; 23(9):1362-7. PubMed ID: 18205769
[TBL] [Abstract][Full Text] [Related]
17. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus.
El-Serag HB; Aguirre TV; Davis S; Kuebeler M; Bhattacharyya A; Sampliner RE
Am J Gastroenterol; 2004 Oct; 99(10):1877-83. PubMed ID: 15447744
[TBL] [Abstract][Full Text] [Related]
18. Non-biopsy detection of intestinal metaplasia and dysplasia in Barrett's esophagus: a prospective multicenter study.
Sharma P; Marcon N; Wani S; Bansal A; Mathur S; Sampliner R; Lightdale C
Endoscopy; 2006 Dec; 38(12):1206-12. PubMed ID: 17163320
[TBL] [Abstract][Full Text] [Related]
19. [Association between symptomatic gastroesophageal reflux and Barrett's esophagus].
Trujillo-Benavides OE; Baltazar-Montúfar P; Angeles-Garay U; Ramírez-Mendoza P; Navarro-García AM; Paredes-Cruz E; Méndez del Monte R; Guerrero-Hernández M
Rev Gastroenterol Mex; 2005; 70(1):14-9. PubMed ID: 16170957
[TBL] [Abstract][Full Text] [Related]
20. Frequency of Barrett's neoplasia after initial negative endoscopy with biopsy: a long-term histopathological follow-up study.
Vieth M; Schubert B; Lang-Schwarz K; Stolte M
Endoscopy; 2006 Dec; 38(12):1201-5. PubMed ID: 17163319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
